Trial intelligence / Profile preview

SQ-129 Intravitreal Sustained-release Injection in Diabetic Macular Edema

CTR20254540Phase 2Active

Sponsor
Xingqi Eye Medicine
Start
Nov 2025
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of SQ-129 in diabetic macular edema (DME), sponsored by Xingqi Eye Medicine. Started Nov 2025; status: active.

02

Drugs

SQ-129
03

Conditions

diabetic macular edema (DME)

Beyond the preview

Go deeper on CTR20254540.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20254540.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call